Kamada Ltd. (KMDA): Price and Financial Metrics
GET POWR RATINGS... FREE!
KMDA Stock Summary
- KAMADA LTD's market capitalization of $192,639,114 is ahead of 27.24% of US-listed equities.
- With a year-over-year growth in debt of 385.74%, KAMADA LTD's debt growth rate surpasses 95.42% of about US stocks.
- Over the past twelve months, KMDA has reported earnings growth of -285.35%, putting it ahead of only 5.61% of US stocks in our set.
- If you're looking for stocks that are quantitatively similar to KAMADA LTD, a group of peers worth examining would be FEIM, NURO, CRNT, SRI, and WPRT.
- KMDA's SEC filings can be seen here. And to visit KAMADA LTD's official web site, go to www.kamada.com.
KMDA Valuation Summary
- KMDA's price/sales ratio is 1.7; this is 15% lower than that of the median Healthcare stock.
- Over the past 116 months, KMDA's price/sales ratio has gone down 3.1.
Below are key valuation metrics over time for KMDA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| KMDA | 2022-11-25 | 1.7 | 1.1 | -18.8 | -20.1 |
| KMDA | 2022-11-23 | 1.7 | 1.1 | -18.7 | -20.1 |
| KMDA | 2022-11-22 | 1.7 | 1.1 | -18.8 | -20.2 |
| KMDA | 2022-11-21 | 1.9 | 1.2 | -17.3 | -18.2 |
| KMDA | 2022-11-18 | 1.9 | 1.2 | -17.5 | -18.5 |
| KMDA | 2022-11-17 | 1.9 | 1.2 | -17.3 | -18.2 |
KMDA Growth Metrics
- The 4 year net income to common stockholders growth rate now stands at 434.86%.
- Its 3 year cash and equivalents growth rate is now at -0.32%.
- The 3 year price growth rate now stands at -14.26%.
The table below shows KMDA's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 115.369 | 16.875 | -10.274 |
| 2022-06-30 | 106.186 | 8.711 | -11.603 |
| 2022-03-31 | 106.835 | -5.456 | -6.745 |
| 2021-12-31 | 103.642 | -8.819 | -2.23 |
| 2021-09-30 | 103.715 | 8.899 | 4.408 |
| 2021-06-30 | 116.006 | 9.189 | 12.088 |
KMDA Price Target
For more insight on analysts targets of KMDA, see our KMDA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $11.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
KMDA Stock Price Chart Interactive Chart >
KMDA Price/Volume Stats
| Current price | $4.45 | 52-week high | $6.96 |
| Prev. close | $4.31 | 52-week low | $4.11 |
| Day low | $4.23 | Volume | 205,400 |
| Day high | $4.55 | Avg. volume | 27,516 |
| 50-day MA | $4.48 | Dividend yield | N/A |
| 200-day MA | $4.96 | Market Cap | 199.36M |
Kamada Ltd. (KMDA) Company Bio
Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The company was founded in 1990 and is based in Ness Ziona, Israel.
Latest KMDA News From Around the Web
Below are the latest news stories about KAMADA LTD that investors may wish to consider to help them evaluate KMDA as an investment opportunity.
AcuCort signs its first commercial agreement for the company's drug Zeqmelit™AcuCort AB (publ) (Spotlight Stock Market: ACUC) today announces that the company has signed an exclusive commercial agreement with the global biopharmaceutical company Kamada Ltd., (NASDAQ: KMDA; TASE: KMDA.TA). The agreement gives Kamada the exclusive right to the marketing and sales as well as the distribution of AcuCort's drug Zeqmelit™ for, among other things, the treatment of acute allergy on the Israeli market. |
Kamada (KMDA) Q3 Earnings and Revenues Top EstimatesKamada (KMDA) delivered earnings and revenue surprises of 433.33% and 8.26%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
Kamada Reports Strong Third Quarter Financial Results Demonstrating Successful Strategic Transition and Reiterates 2022 Financial GuidanceThird Quarter 2022 Revenues of $32.2 Million, a 40% Increase Compared to Prior Year Period; Reaping the Benefits of the Acquired IgG PortfolioStrong Results Represent Completion of the Company’s Strategic Transformation into a Diversified Commercial Entity with Multiple Growth DriversAdjusted EBITDA for the Third Quarter was $6.0 Million, or 19% Margin and for First Nine Months was $10.6 Million or 13% Margin, Within Annual Guidance, and Representing 58% Increase Year-over-YearGenerated Operatin |
Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2022 Financial Results and Host Conference Call on November 22, 2022REHOVOT, Israel, and HOBOKEN, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that it will release financial results for the third quarter and first nine months ended September 30, 2022, prior to the open of the U.S. financial markets on Tuesday, November 22, 2022. Kamada management will host an investment community conference call on Tuesday, Nov |
Science 37 Holdings, Inc. (SNCE) Reports Q3 Loss, Misses Revenue EstimatesScience 37 Holdings, Inc. (SNCE) delivered earnings and revenue surprises of 5.88% and 21.12%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
KMDA Price Returns
| 1-mo | -5.32% |
| 3-mo | -10.82% |
| 6-mo | -5.32% |
| 1-year | -29.14% |
| 3-year | -40.11% |
| 5-year | -4.81% |
| YTD | -32.37% |
| 2021 | 1.54% |
| 2020 | -5.12% |
| 2019 | 36.60% |
| 2018 | 5.26% |
| 2017 | -12.84% |
Continue Researching KMDA
Want to see what other sources are saying about Kamada Ltd's financials and stock price? Try the links below:Kamada Ltd (KMDA) Stock Price | Nasdaq
Kamada Ltd (KMDA) Stock Quote, History and News - Yahoo Finance
Kamada Ltd (KMDA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...